Relative Molecular Massi
-20 A 5A C
H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 acetate salt
Fields of Applicationi
Acute variceal hemorrhage (esophageal varices)
Norepinephrine-resistant septic shock - not yet an approved application
Terlipressin is a synthetic analog of vasopressin and is used as a vasoactive drug in the management of hypotension.
Terlipressin represents a prodrug, it is converted to (Lys8)- vasopressin (LVP) after removal of the N-terminal
triglycine in vivo. Terlipressin has a longer duration of action and a better safety profile than the parent compound LVP.
Shenzhen JYMed Technology Co., Ltd. (JYMed) founded in 2009, is an innovative pharmaceutical enterprise with independent intellectual property rights in R&D, manufacturing and commercialization of peptide products. There are two subsidiary companies of Shenzhen JX Bio Pharmaceutical Co., Ltd. and Hubei JX Bio Pharmaceutical Co., Ltd. It is initiative to establish the R&D technology platform for peptide products and sustained release pharmaceutical preparation of peptide and protein medicines by JYMed in China. The peptide products in R&D are in the forward position in China and aboard, while the technology is in the domestic leading position and international advanced level. Our company has an excellent R&D team, management team and first-class expert consultant team consisting of professionals including doctors, masters, professors, researchers, senior engineers. Meanwhile, to maximally extend the R&D team by hiring top industry scientists to serve as guest researchers, commissioners, and technical consultants and strengthening technical cooperation with external scientific research units. It has established a good cooperative relationship with famous universities and research institutions such as Southwest University, School of Pharmaceutical Science, Sun Yat-Sen University, Hebei University, Research Institute of Tsinghua University, Southern University of Science and Technology, Shenzhen Technology University, and Shenzhen University. The company has passed the certification of Shenzhen High-tech Enterprise and National High-tech Enterprise. As a domestic enterprise with the advantage of the industrialization of polypeptide APIs, it has achieved a major technological breakthrough in the industrialization of polypeptide APIs with extremely high technical difficulty. With high-quality product quality, the company carries out open R&D CRO services. The market network covers domestic and foreign markets. The cooperation customers are mainly domestic and foreign large-scale new drug R&D and production companies. In recent years, JYMedhas been focusing on R&D and production of peptide. At the same time, the company also has been focusing on the development and industrialization. It has been continually increasing investment in high-end chemical drugs and biological drugs, striving for long-term business operations and develop in an all-round way to create a more prominent corporate competitive advantage. The company is adhering to the enterprise spirit of ÃÂ¢ÃÂÃÂTianjianzhishan, Tianyuanzhihe.ÃÂ¢ÃÂÃÂ We are with a grateful heart and commit to providing reliable medical products for human health all the time. To work hard to become an influential and innovative company in the pharmaceutical industry.
- BUSINESS TYPE Exporter, Manufacturer, Supplier
- EMPLOYEE COUNT 400
- ESTABLISHMENT 2009
- ANNUAL TURNOVER USD 1 Million
- WORKING DAYS Monday To Sunday
- PAYMENT MODE Telegraphic Transfer (T/T)